Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-08-21
2007-08-21
Tucker, Zachary C (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S350000
Reexamination Certificate
active
10915696
ABSTRACT:
Certain substituted imidazo[1,2-a]pyrazines and the pharmaceutically acceptable salts thereof, are provided herein. Pharmaceutical compositions containing one or more compound of Formula I, or a pharmaceutically acceptable salt of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents, are also provided herein.Methods of treating patients suffering from certain diseases and disorders responsive to EphB4 kinase modulation, which comprise administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder are disclosed.Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with one or more other therapeutic agents.A method for determining the presence or absence of an angiogenic kinase in a sample comprising contacting the sample with a compound of Formula I under conditions that permit detection of activity of the angiogenic kinase, detecting a level of the activity of the angiogenic kinase, and therefrom determining the presence or absence of the angiogenic kinase in the sample.
REFERENCES:
patent: 5593997 (1997-01-01), Dow et al.
patent: 5658857 (1997-08-01), Andree et al.
patent: 5783576 (1998-07-01), Roos et al.
patent: 6919340 (2005-07-01), Currie et al.
patent: 6919341 (2005-07-01), Paruch et al.
patent: 7160885 (2007-01-01), Currie et al.
patent: 2003/0212073 (2003-11-01), Currie et al.
patent: 2004/0063715 (2004-04-01), Paruch et al.
patent: 2004/0067951 (2004-04-01), DeSimone et al.
patent: 2004/0072835 (2004-04-01), Paruch et al.
patent: 2004/0220189 (2004-11-01), Sun et al.
patent: 2005/0009832 (2005-01-01), Sun et al.
patent: 2005/0054648 (2005-03-01), Mitchell et al.
patent: 2005/0054649 (2005-03-01), Currie et al.
patent: 0 43 37 609 (1995-05-01), None
patent: 0 480 713 (1992-04-01), None
patent: WO88/04298 (1988-06-01), None
patent: WO95/12594 (1995-05-01), None
patent: WO96/04298 (1996-02-01), None
patent: WO96/34866 (1996-11-01), None
patent: WO99/28322 (1999-06-01), None
patent: WO 01/27119 (2001-04-01), None
patent: WO 02/10170 (2002-02-01), None
patent: WO 02/30428 (2002-04-01), None
patent: WO 02/060492 (2002-08-01), None
patent: WO 02/066481 (2002-08-01), None
patent: WO 02/076985 (2002-10-01), None
patent: WO 03/070732 (2003-08-01), None
patent: WO 03/089434 (2003-10-01), None
patent: WO 2004/022562 (2004-03-01), None
patent: WO 2004/026310 (2004-04-01), None
patent: WO 2004/026877 (2004-04-01), None
patent: WO 2004/072080 (2004-08-01), None
patent: WO 2004/072081 (2004-08-01), None
patent: WO 2005/019220 (2005-03-01), None
Ding et al. (2002) “A Combinatorial Scaffold Approach toward Kinase-Directed Heterocycle Libraries,” J. Am. Chem. Soc., 124(8): 1594-1596.
Hanks (Apr. 1, 1994) “Hanks Classification: Protein Kinase Classification, provided by Steven K. Hanks,” pp. 1-4, from http://pkr.sdsc.edu/html/pk—classification/pk—catalytic/pk—hanks—class.html.
Jeffrey et al. (1998) “Phosphodiesterase III and V Inhibitors on Pulmonary Artery from Pulmonary Hypertensive Rats: Differences Between Early and Established Pulmonary Hypertension,” J. Cardiovascular Pharmacology, 32:213-219.
Lumma Jr. et al. (1983) “Piperazinylimidazo[1,2-a]pyrazines with Selective Affinity for in Vitro alpha-Adrenergic Receptor Subtypes,” J. Med. Chem., 26:357-363.
“Protein Kinases in Disease,” references produced from a Sep. 24, 1997, search of the On-line Meddelian Inheritance in Man (OMIM) database, pp. 1-11, from http://bioinformatics.weizmann.ac.il/Kinases/pkr/pk—medicine.html.
Stenberg et al. (2000) “KinMutBase, a database of human disease-causing protein kinase mutations,” Nucleic Acids Research, 28(1):369-371.
Vitse et al. (1999) “New Imidazo[1,2-a]pyrazine Derivatives with Brochodilatory and Cyclic Nucleotide Phosphodiesterase Inhibitory Activities,” Bioorganic & Medicinal Chemistry, 7: 1059-1065.
Restriction Requirement dated Oct. 20, 2004, for U.S. Appl. No. 10/419,682, filed Apr. 21, 2003.
International Search Report dated Oct. 22, 2003, for Application No. PCT/US03/12222, International filing date Apr. 21, 2003.
Written Opinion dated Dec. 5, 2003, for Application No. PCT/US03/12222, International filing date Apr. 21, 2003.
Second Written Opinion dated Apr. 13, 2004, for Application No. PCT/US03/12222, International filing date Apr. 21, 2003.
International Preliminary Examination Report dated Aug. 3, 2004, for Application No. PCT/US03/12222, International filing date Apr. 21, 2003.
International Search Report dated Feb. 9, 2004, for Application No. PCT/US03/28329, International filing date Sep. 9, 2003.
Written Opinion dated Jul. 6, 2004, for Application No. PCT/US03/28329, International filing date Sep. 9, 2003.
International Preliminary Examination Report dated Oct. 27, 2004, for Application No. PCT/US03/28329, International filing date Sep. 9, 2003.
International Search Report and Written Opinion dated Jul. 7, 2004, for Application No. PCT/US2004/003922, International filing date Feb. 10, 2004.
International Search Report and Written Opinion dated Jul. 7, 2004, for Application No. PCT/US2004/003923, International filing date Feb. 10, 2004.
International Search Report and Written Opinion dated Dec. 8, 2004, for Application No. PCT/US2004/021150, International filing date Jun. 30, 2004.
International Search Report and Written Opinion dated Feb. 1, 2005, for Application No. PCT/US2004/025884, International filing date Aug. 11, 2004.
Office Action dated Apr. 3, 2006, for U.S. Appl. No. 10/776,002, filed Feb. 10, 2004.
Office Action dated May 24, 2006, for U.S. Appl. No. 10/776,631, filed Feb. 10, 2004.
Notice of Allowance dated Aug. 11, 2006, for U.S. Appl. No. 10/776,002, filed Feb. 10, 2004.
Notice of Allowance dated Sep. 7, 2006, for U.S. Appl. No. 10/776,631, filed Feb. 10, 2004.
Office Action dated Sep. 26, 2006, for U.S. Appl. No. 10/658, 121, filed Sep. 9, 2003.
Danca M. Diana
Darrow James W.
DeSimone Robert W.
Mitchell Scott A.
Pippin Douglas A.
CGI Pharmaceuticals, Inc.
Finnegan Henderson Farabow Garrett & Dunner LLP
Tucker Zachary C
LandOfFree
Certain substituted imidazo[1,2-a]pyrazines, as modulators... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Certain substituted imidazo[1,2-a]pyrazines, as modulators..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Certain substituted imidazo[1,2-a]pyrazines, as modulators... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3891600